MergerLinks Header Logo

Announced

Completed

An investor consortium led an additional $55m funding in Series B2 round in Enveda Biosciences.

Synopsis

An investor consortium led an additional $55m funding in Series B2 round in Enveda Biosciences, a biotechnology company using AI to translate nature into new medicines, with participation from Premji Invest, Lingotto Investment Fund, Microsoft, The Nature Conservancy, Kinnevik, True Ventures, FPV, Level Ventures, and Jazz Venture Partners. “The investors who joined in this round recognize our rapid progress, as well as our expansive potential and vision. In combination with our deep bench of top tier investors, we are in an ideal position to advance our novel medicines into the clinic and to bring hope to waiting patients,” Viswa Colluru, Enveda CEO and Founder.

Show Details & Financials

Market Context

Sort

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US